On Dec 8, Biolidics announced it has entered into a definitive agreement with its contract manufacturer for the production of its ClearEpi SARS-CoV-2 Neutralising Antibody Rapid Test Kit (ClearEpi NAB Test) which can be used to detect a person's protective immunity against Covid-19 infections.
The company has also obtained the relevant product liability insurance for the ClearEpi NAB Test.
According to Biolidics, commercial production for the ClearEpi NAB Test is expected to commence in the current financial year ending Dec 31.
Biolidics states that unlike most commercially available Covid-19 serology tests which test for IgM/ IgG antibodies in patients, the ClearEpi NAB Test detects neutralising antibodies in serum or plasma which provides an indication of an individual's protective immunity against Covid-19.
To that end, the company says the ClearEpi NAB Test can potentially serve as an important tool to assist in the area of assessing vaccine efficacy, vaccine deployment and social activities management.
The ClearEpi NAB Test was developed by Biolidics with technology licensed from the Agency for Science, Technology and Research (A*STAR)’s Accelerate Technologies (A*ccelerate).
See also: BioNTech beats estimates as vaccine maker pursues more diseases
In September, the company received confirmation for the CE marking for the ClearEpi NAB Test which enables the Company to market and sell the ClearEpi NAB Test in the European Union.
As at 9.11am, shares in Biolidics are up 1.8 cents or 10.47% higher at 19 cents.
